8-KEarnings & ResultsRegulation FDExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 31, 2025)

Filed July 31, 2025For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) has filed an 8-K report on July 31, 2025, to disclose its financial results for the second quarter of 2025. The filing primarily serves to furnish the earnings press release and a related presentation, both of which are available on the company's website. These documents contain detailed financial performance information, including both GAAP and non-GAAP measures, which investors should review for a comprehensive understanding of the company's operational and financial condition during the quarter. The earnings press release and presentation provide crucial insights into BMY's performance, strategic initiatives, and outlook. Investors are encouraged to access these furnished exhibits for specifics on revenue, profitability, and any forward-looking statements or strategic developments discussed. The company has also highlighted that reconciliations between GAAP and non-GAAP figures are available within these provided materials.

Key Highlights

  • 1BMY filed an 8-K on July 31, 2025, reporting on its Q2 2025 financial results.
  • 2The filing includes the Q2 2025 earnings press release and a related investor presentation as furnished exhibits.
  • 3Both GAAP and non-GAAP financial information are presented, with reconciliations available.
  • 4The earnings materials are accessible via the company's website (www.bms.com).
  • 5The company is providing these updates in conjunction with its Q2 2025 earnings conference call and webcast.
  • 6Information furnished under Regulation FD is not considered 'filed' for Section 18 purposes, but is crucial for investor understanding.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially announce and provide access to Bristol-Myers Squibb Company's financial results for the second quarter of 2025, along with related presentation materials.

The detailed financial results for Q2 2025 are contained within the earnings press release (Exhibit 99.1) and the Bristol Myers Presentation (Exhibit 99.2) furnished with this 8-K filing. These documents are also available on the company's website at www.bms.com.

Yes, the earnings press release and the presentation include references to non-GAAP financial information. Reconciliations between these non-GAAP measures and their comparable GAAP financial measures are provided within the earnings press release.

Information furnished under Item 7.01 (Regulation FD Disclosure), including the press release and presentation, is generally not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. However, it is important for investors to review this information for understanding company performance.